The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Table 3 Baseline model parameters (based on [2, 4])

Parameter	Hydrocele average estimate	Lymphedema average estimate	Source
Acute Disease
Percentage of clinical patients who experience ADL episodes per year	70 %	95 %	[8, 10–17]
Frequency of ADL episodes for clinical patients (in absence of MDA)	2 per year	4 per year	[8, 10–17]
Average duration of an ADL episode	4 days	4 days	[8, 10–17]
Reduction in the frequency of ADL episodes by MDA	50 %	50 %	[33, 36, 37]
Chronic Disease
Percentage in different clinical disease states	62.5 %	37.5 %	[7]
Percentage of chronic disease alleviated by MDA	10 %	15 %	[20, 30–35]

Due to the lack of region-specific data, a standard rate or proportion was utilized for each GPELF country. ADL acute adenolymphangitis, MDA mass drug administration

ISSN: 2049-9957